RT Journal Article
SR Electronic
T1 Lower regional gray matter volume in the absence of higher cortical amyloid burden in late-life depression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.08.21250568
DO 10.1101/2021.02.08.21250568
A1 Akihiro Takamiya
A1 Thomas Vande Casteele
A1 Michel Koole
A1 François-Laurent De Winter
A1 Filip Bouckaert
A1 Jan Van den Stock
A1 Stefan Sunaert
A1 Patrick Dupont
A1 Rik Vandenberghe
A1 Koen Van Laere
A1 Mathieu Vandenbulcke
A1 Louise Emsell
YR 2021
UL http://medrxiv.org/content/early/2021/02/10/2021.02.08.21250568.abstract
AB Late-life depression (LLD) is associated with a risk of developing Alzheimer’s disease (AD). However, the role of AD-pathophysiology in LLD, and its association with clinical symptoms and cognitive function are elusive. In this study, one hundred subjects underwent amyloid positron emission tomography (PET) imaging with [18F]-flutemetamol and structural MRI: 48 severely depressed elderly subjects (age 74.1±7.5 years, 33 female) and 52 age-/gender-matched healthy controls (72.4±6.4 years, 37 female). The Geriatric Depression Scale (GDS) and Rey Auditory Verbal Learning Test (RAVLT) were used to assess the severity of depressive symptoms and episodic memory function respectively. Amyloid deposition was quantified using the standardized uptake value ratio. Whole-brain voxel-wise comparisons of amyloid deposition and gray matter volume (GMV) between LLD and controls were performed. Multivariate analysis of covariance was conducted to investigate the association of regional differences in amyloid deposition and GMV with clinical factors, including GDS and RAVLT. As a result, there were no significant group differences in amyloid deposition. In contrast, LLD showed significant lower GMV in the left temporal and parietal region. GMV reduction in the left temporal region was associated with episodic memory dysfunction, but not with depression severity. Regional GMV reduction was not associated with amyloid deposition. LLD is associated with lower GMV in regions that overlap with AD-pathophysiology, and which are associated with episodic memory function. The lack of corresponding associations with amyloid suggests that lower GM driven by non-amyloid pathology may play a central role in the neurobiology of LLD presenting as a psychiatric disorder.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare; All authors have nothing to declare in relation to this work; A. Takamiya has received grants from Keio University Medical Science Fund and Kanae Foundation for the Promotion of Medical Science; R. Vandenberghe has received funding from the Foundation for Alzheimer Research (SAO-FRMA) (09013, 11020, 13007) and KU Leuven (OT/08/056, OT/12/097), and he has received consultancy agreement from AC Immune, and his institution has a clinical trial agreement with AbbVie and Roche; K. Van Laere has received contract research grants through KU Leuven from Merck, Janssen Pharmaceuticals, Abide, UCD, Cerveau, Syndesi, Eikonizo, GE Healthcare, and Curasen, and he has received speaker fees from GE Healthcare.Clinical TrialEudraCT 2009-018064-95Funding StatementThis study was supported by Research Foundation Flanders (FWO) project G.0746.09 (M. Vandenbulcke), G0C0319N (M. Vandenbulcke, F. Bouckaert, L. Emsell), Research Grant Old Age Psychiatry UZ Leuven R94859 (M. Vandenbulcke), KU Leuven C24/18/095 (M. Vandenbulcke, F. Bouckaert, J. Van den Stock, L. Emsell), KU Leuven Sequoia Fund; The tracer [18F]-flutemetamol was provided free of charge by GE for this investigator led study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the ethical committee of the University Hospitals Leuven (protocol S52151)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available.